67 223

Cited 9 times in

Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.

DC Field Value Language
dc.contributor.authorKang, BW-
dc.contributor.authorLee, D-
dc.contributor.authorChung, HY-
dc.contributor.authorHan, JH-
dc.contributor.authorKim, YB-
dc.date.accessioned2014-05-02T05:16:45Z-
dc.date.available2014-05-02T05:16:45Z-
dc.date.issued2013-
dc.identifier.issn0171-5216-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/9894-
dc.description.abstractPURPOSE: Tetraspanin CD151 is known to be involved in cancer invasion and metastasis, and its overexpression appears to be associated with a poor prognosis for various types of cancer. However, the expression status of CD151 and its prognostic impact in advanced gastric cancer (AGC) has not yet been clarified.



METHODS: Immunohistochemistry was used to investigate the expression of CD151, c-erbB2, and c-Met in 159 cases of AGC. The clinicopathological and prognostic significance of these biomarkers were then evaluated.



RESULTS: The overexpression of CD151 was observed in a subset of advanced gastric adenocarcinomas (25.8 %), and c-erbB2 and c-Met were overexpressed in 15.1 and 35.2 % of the cohort, respectively. CD151 overexpression was more frequently observed in tumors from younger patients (P = 0.028). There were close associations between CD151 and c-erbB2 overexpression (P = 0.033) and between c-erbB2 and c-Met overexpression (P = 0.001). CD151 overexpression was closely correlated with patient' overall survival (OS; P < 0.001) and disease-free survival (DFS; P < 0.001). Furthermore, the expression rate of CD151 seemed to increase gradually according to the depth of invasion (T stage) (χ(2) test for trend; P = 0.101), N stage (P = 0.238), and pathologic stage (P = 0.153), although trends were not statistically significant. In a multivariate analysis, CD151 overexpression was an independent prognostic factor predicting worse OS (P = 0.002) and DFS (P = 0.005), along with the T and N stage.



CONCLUSIONS: CD151 was found to be an independent prognostic marker for patients with AGC.
-
dc.language.isoen-
dc.subject.MESHAdenocarcinoma/enzymology/immunology/metabolism/therapy-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntigens, CD151/*biosynthesis-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHCohort Studies-
dc.subject.MESHDigestive System Surgical Procedures-
dc.subject.MESHDrug Combinations-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHImmunohistochemistry-
dc.subject.MESHLymph Node Excision-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOxonic Acid/administration & dosage-
dc.subject.MESHPilot Projects-
dc.subject.MESHPrognosis-
dc.subject.MESHReceptor Protein-Tyrosine Kinases/biosynthesis-
dc.subject.MESHReceptor, erbB-2/biosynthesis-
dc.subject.MESHStomach Neoplasms/enzymology/immunology/*metabolism/therapy-
dc.subject.MESHTegafur/administration & dosage-
dc.subject.MESHTumor Markers, Biological/biosynthesis-
dc.subject.MESHYoung Adult-
dc.titleTetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.-
dc.typeArticle-
dc.identifier.pmid24005419-
dc.contributor.affiliatedAuthor이, 다근-
dc.contributor.affiliatedAuthor한, 재호-
dc.contributor.affiliatedAuthor김, 영배-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s00432-013-1503-4-
dc.citation.titleJournal of cancer research and clinical oncology-
dc.citation.volume139-
dc.citation.number11-
dc.citation.date2013-
dc.citation.startPage1835-
dc.citation.endPage1843-
dc.identifier.bibliographicCitationJournal of cancer research and clinical oncology, 139(11):1835-1843, 2013-
dc.identifier.eissn1432-1335-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
fulltext not available.txtDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse